A phase I/II trial of MEK162 in combination with gemcitabine (G) and cisplatin (C) for patients (pts) with untreated advanced biliary cancer (ABC). Combined treatment with TLR7/8 agonists and carbon ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results